Abstracts


file

Fleming Ballweber L, Andersen-Nissen E, Fiore-Gartland A, Naidoo AF, Carpp LN, Harper MS, DiazGranados C, Phogat S, Huang Y, Gray G, McElrath MJ and NIAID HIV Vaccine Trials Network. Systems analysis of the innate and adaptive immune responses to the RV144 ALVAC HIV vaccine in a South African HIV uninfected cohort. Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Fleming Ballweber L, Cohen KW, Nelson R, Seese A, Huynh C, Varni A,  Moodie Z, Tomaras G, Phogat S, DiazGranados C, Koutsoukos M, Laher F, Bekker LG, McElrath MJ for the HVTN 100 Team. Expansion of VH1-2*02 Env-specific B Cells in a Non-neutralizing HIV-1 Env Vaccine Regimen. Oral Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Kobie J, Basu M, Piepenbrink M, Francois C, Roche F, Fucile C, Rosenberg A, Liesveld J and Keefer M. Induction and Relationship of HIV Envelope-Specific B cells in the Peripheral Blood and Bone Marrow Following Vaccination in Humans. Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Frahm N, Fiore-Gartland A, Malhi  H, Baden LR, Walsh SR, Cohen KW, Elizaga ML, Goepfert PA, Edupuganti S, Pantaleo G, Buchbinder S, Mayer K, Pensiero M, Robb ML, Corey L, Hutter J, Haynes BF, Korber BT, Gilbert PB, McElrath MJ. Increased Breadth of T-Cell Responses After Mosaic HIV Vaccination in Humans (HVTN 106). Oral Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Wilson GJ, Rodriguez B, Elizaga M, Li S, Allen M, Frank, Thommes E, Trahey M, Kalams S, Pensiero M, Butler C, Hannaman D, Clarke DK, Xu R, Egan M, Eldridge J, Montefiori D, Tomaras G, Frahm N, and HIV Vaccine Trials Network. Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial. Oral Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Boppana S, Sterett S, Bansal A, Goepfert P. Vaccine-Encoded Adapted Epitopes Infrequently Induce CD8 T Cell Responses. Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Shen X, Moodie Z, McMillan S, Goodman D, Yates NL, Spreng R, Grunenberg N, Gilbert P, Laher F, Bekker LG, Gray G, Corey L, McElrath MJ, Ferrari G, Tomaras G and the HVTN 097 and HVTN 100 Study Teams. V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa. Oral Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Seaton K, Palli R, Key M, Heptinstall J, Brackett C, Fuchs J, Buchbinder S, Goepfert P, Robinson H, Graham B,  Maenza J, HVTN 077, 094, 105, 204, 205, and 910 Teams, Hural J, Janes H, Huang Y, McElrath J, Keefer M, Kobie J, Tomaras G, Thakar J. Impact of Vaccine Regimen on Vaccine Induced Antibody Durability. Oral Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Broder G, Lucas J, Davis J, Wallace S, Luthuli N, Baepanye K, White R, Bolton M, Blanchette C, Andrasik M. Standardized Metrics Can Reveal Region-Specific Opportunities in Community Engagement to Aid Recruitment in HIV Prevention Trials. Oral Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Magaret CA, Williamson BD, Borate B, Carpp L, Georgiev I, Setliff I, Dingens AS, Benkeser DC, Simon N, Carone M, Montefiori D, Alter G, Yu WH, DeCamp AC, Juraska M, Edlefsen PT, Karuna S, Mgodi NM, Edugupanti S, Gilbert PB. Prediction of VRC01 Neutralization Sensitivity by HIV-1 gp160 Sequence Features. Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Behrens S, LaBranche CC, Zhou T, Wiehe K, Bonsignori M, Sattentau QJ, Eaton A, Greene K, Gao H, Williams WB, Saunders K, Perez LG, Korber BT, Kwong PD, Mascola JR, McGuire AT, Stamatatos L, Acharya P, Haynes BF and Montefiori DC. Germline-Targeting and Reverse Engineering to Elicit CH235.12 Lineage BNAbs. Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Cram JA, Fiore-Gartland A, Srinivasan S, Karuna S, Pantaleo G, Fredricks D and Kublin J. Human Gut Microbiota are Associated with HIV-reactive Immunoglobulin at Baseline and Following HIV Vaccination. Late Breaker Oral Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Edupuganti S, De Rosa S, Huang Y, Han X, Shao M, Elizaga M, Swann E, Polakowski L, Kalams S, Keefer M, Maenza J, Tomaras G, Wise MC, Morrow MP, Khan AS, Boyer J, Pensiero M, Sardesai NY, Bagarazzi ML and Weiner DB. Immune Responses to PENNVAX-GP® HIV DNA Vaccine plus IL-12 are Equivalent or Superior when Delivered by Intradermal vs. Intramuscular Electroporation. Late Breaker Oral Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Cohen K, Malahleha M, Laher F, Bekker LG, Mngadi K, Daniels B, Innes C, Moodie Z, Grunenberg N, Allen M, Grant S, Yu C, Phogat S, DiazGranados C, Koutsoukos M, Tomaras G, Kublin J, Corey L, Gray G, McElrath MJ, on behalf of the HVTN 100 Study Team. Increase in Env-Specific Binding Antibody and CD4+ T Cell-Responses After Month 30 Boost of gp120/MF59 Delivered Alone or with ALVAC-HIV. Late Breaker Oral Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Hosseinipour M, Innes C, Naidoo S, Tomaras G, Morris L, DeCamp A, Metch B, Mann P, Frahm N, Hutter J, Ramjee G, Sebe M, Maganga L, Herce M, Pantaleo G, Koutsoukos M, Marshall K, McElrath MJ, Corey L and Kublin JG. Co-administration of 3 doses of DNA/Protein Improves Antibody Responses to a Prime-Boost Approach, but Needle-Free Injection of DNA Shows No Benefit. Late Breaker Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Goepfert PA, Casapia M, Elizaga M, Huang Y, Hutter J, Yu C, Seaton K, Tomaras G, DeRosa S, Montefiori D, Kelly C, Valencia J, Baden L, Sobieszczyk ME, Koblin B, Keefer M, Buchbinder S, McElrath MJ, Lee C and Robinson H. HVTN114: A Phase 1 Trial to Evaluate Late Boosts with AIDSVAX B/E of Participants Previously Vaccinated with MVA/HIV62B in DNA/MVA or MVA Regimens. Late Breaker Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Lemos MP, Astronomo RD, Andersen-Nissen E, Huang Y, Shao M, Mann P, Czartoski  J, Orell C, Naidoo A, Mgaga Z, Glantz H, Gomez R, Westerberg K, Hural J, Hutter J, Mascola J, Ochsenbauer C, Ledgerwood J, Bekker LG and McElrath MJ on behalf of the HVTN116 Protocol Team. Rectal Biopsies from Men and Women Infused Intravenously with VRC01 mAb Show Partial Protection that Wanes Over Time in Ex Vivo HIV-1 Challenges. Late Breaker Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Tomaras GD, Montefiori D, KW Cohen, Heptinstall J, De Rosa SC, Sawant S, Baden LR, Goepfert PA, Keefer MC, Edupuganti S, Stieh D, Hendriks J, Moodie Z, Corey L, Kublin JG, MJ McElrath, Nijs S, Frahm N. Tetravalent Janssen Mosaic Ad26/Protein HIV vaccine shows increased Clade C Env-specific CD4+ T-Cell and Antibody Responses versus trivalent vaccine. Late Breaker Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Stieh DJ, Callewaert K, Sarnecki M, Hendriks J, Nijs S, Euler Z, Schuitemaker H, Tomaras GD, Kublin J, Corey L, McElrath MJ, Ake J, Robb ML, Alter G, Barouch DH, Pau MG and Tomaka FL. Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens. Late Breaker Oral Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Moodie Z, Innes C, Hosseinipour M, Naidoo S, Bekker LG, Laher F, Grunenberg N, Mann P, Yu C, McElrath MJ, Tomaras G, Yates N, Morris L, Mkhize N, Montefiori D, Allen M, Kublin J, Gray G, Gilbert P, Corey L and the HVTN 100 and HVTN 111 trial teams. DNA-prime Induces Higher Magnitude Humoral Responses than ALVAC-prime in HIV Vaccine Regimens with the Same Protein Boost. Late Breaker Oral Presentation. HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Edupuganti S, Mgodi N, Karuna S, Andrew P, Kochar N, De Camp A, Takuva S, Anderson M, De La Greca R, Gomez Lorenzo M, Burns D, Frank I, Sobieszczyk M, Cabello R, Gonzales P, Naicker K, Garnett P, Mascola J, Cohen M, Corey L and the HVTN 704/HPTN 085 & HVTN 703/HPTN 081 Protocol Teams. Antibody Mediated Prevention: Proof-of-Concept, Randomized, Blinded, Placebo-Controlled Trials to Assess Safety and Efficacy of VRC01 to Prevent HIV-1. Late Breaker Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Andrew P, Andrasik M, Thommes E, deCamp A, Kochar N, Karg C, Greene E, Tindale I, Lucas J, Broder G, Wallace S, Oseso L, Gomez Lorenzo M, Burns D, Edupuganti S, Mgodi N, Cohen M, Corey L, Karuna S and the AMP Protocol Teams. Retention in the Ongoing AMP Trials of VRC01, a Broadly Neutralizing Antibody (bnAb) to Prevent HIV in Women, MSM & Transgender (TG) People. Late Breaker Poster Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018

Huang Y, Pegu A, Huang Y, Pauthner M, Corey L, Gilbert P, Burton D and Mascola J. A meta-analysis to evaluate the relationship between serum antibody neutralizing titer and protection against SHIV challenge in nonhuman primates for 16 broadly neutralizing HIV antibodies. Late Breaker Oral Presentation, HIVR4P 2018, Madrid, Spain, October 21-25, 2018


file

Broder G, Lucas J, Davis J, Wallace S, Luthuli N, Baepanye K, White R, Blanchette C, Andrasik M. Toward Standardized Metrics for the Conduct of Community Engagement in HIV Biomedical Prevention Research Studies. Poster Presentation, AIDS 2018, Amsterdam, Netherlands, July 23-27, 2018.


Keystone Symposia

Cohen KW, Nelson R, Seese A, Fleming L, Tomaras G, Moodie Z, Phogat S, Laher F, Bekker LG, McElrath MJ for the HVTN 100 Team. Expansion of VH1-2*02 Env-specific B cells by vaccination. Oral and Poster Presentation, Keystone: Progress and Pathways Toward an Effective HIV Vaccine, Banff, AB, Canada, January 28 - February 1, 2018

Boppana S, Sterett S, Qin K, Goepfert P. Vaccine-induced CD8 T cell cross-reactivity is diminished compared to natural infection and does not impact viral load in HIV-1 vaccine recipients who became infected. Poster Presentation, Keystone: Progress and Pathways Toward an Effective HIV Vaccine, Banff, AB, Canada, January 28 - February 1, 2018

Reeves D, Duke E, Huang Y, Gilbert P, Schiffer J. Viral dynamics model illustrates diverse outcomes in simulated AMP trials. Poster Presentation, Keystone: Progress and Pathways Toward an Effective HIV Vaccine, Banff, AB, Canada, January 28 - February 1, 2018


file

Musuruana M, Koblin B, Lucy D, Ortiz G, McCrossin J, Usher D, Tieu HV. A pilot study comparing sexual risk data collected via smartphone app diaries and online survey questionnaire among at-risk HIV negative men who have sex with men. Poster Presentation, IAS 2017, Paris, France, July 23-26, 2017

Laher F, Bekker LG, Moodie Z, Grunenberg N, Allen M, Cohen K, Frahm N, Malahleha M, Mngadi K, Daniels B, Innes C, Grant S, Yu C, Gilbert P, Phogat S, DiazGranados C, Koutsoukos M, van der Meeren O, Bentley C, Pensiero M, Mehra V, Kublin J, Corey L, Gray GE, Montefiori DC, Morris L, McElrath MJ, Tomaras GD, HVTN 100 Study Team. HVTN 100: The effects of a 12-month booster on immune responses in healthy HIV-uninfected adults vaccinated with ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in South Africa.  Late Breaker Poster Presentation, IAS 2017, Paris, France, July 23-26, 2017


Keystone Symposia

Baxter AE, Morou A, Ballweber-Fleming L, McNevin J, HVTN team, Tomaras G, McElrath MJ, Andersen-Nissen E and Kaufmann DE. Magnitude of HIV vaccine-specific pTfh and non-Tfh response is associated with phenotype skewing and humoral immunity. Poster Presentation, Keystone B Cell and T Follicular Helper Cells Meeting, Whistler, BC, Canada, April 23-27, 2017

Martins KM, Migueles SA, Frahm N, Rosenthal D, Gavil NV, Wang LA, Toulmin SA, Kelly EP, McElrath MJ, Connors M. Low HIV-Specific CD8+ T-Cell Cytotoxic Capacity in Ad5/HIV Vaccinees Is Associated with Reduced Extracellular Levels of Functional Lytic Proteins.  Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Cohen KW, Nelson R, Thayer C, Morris D, De Rosa S, Frahm N, Barnett SW, Montefiori D, Spearman P, Tomaras G, McElrath MJ. Detection of durable vaccine-induced HIV Env-specific memory B cells. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Andersen-Nissen E, Ballweber-Fleming L, Naidoo AF, Harper MS, Fiore-Gartland A, Huang Y, Gray G, McElrath MJ and NIAID HIV Vaccine Trials Network. Systemic innate immune responses in South Africans to the RV144 ALVAC HIV vaccine. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Narpala SR, Prabhakaran M, Astronomo RD, Lemos MP, Westerberg K, Fleming L, Gross M, Ledgerwood JE, McElrath MJ, Mascola J, Koup RA and McDermott AB. Development of a custom ultra-sensitive Singulex Single Molecule Counting (SMC) immunoassay for quantification of VRC01 in serum and mucosal clinical trial samples. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Ditse Z, Mkhize N, Yin M, Keefer M, Montefiori D, Tomaras G, Churchyard G, Karuna S, Morgan C, Bekker LG, Gray G, Mlisana K, Williamson C and Morris L and the NIAID HIV Vaccines Trials Network. Vaccination does not impact development of binding and neutralization responses in HIV-1 breakthrough infections. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Auclair S, Liu F, Churchyard G, Morgan C, Frahm N, Robb M, Kim J, Michael N, Hu H. Distinct HIV susceptibility of different HIV vaccine vector-specific CD4 T cells. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017

Seaton K et al. Individual-level meta-analysis of HIV-1 Vaccine Elicited Mucosal Antibodies in Human Volunteers. Poster Presentation, Keystone HIV Vaccines, Steamboat Springs, CO, USA, March 26-30, 2017


file

Van Tieu H, Lemos M, Andrasik M, Fleming I, Nandi V, Ortiz G, Lucy D, Musuruana M, McElrath MJ, Koblin BA. Acceptability of self-collected rectal swabs for HIV exposure testing among MSM/TGW. Poster Presentation, CROI 2017, Seattle, WA, USA, February 13-16, 2017

Huang Y, Zhang L, Grunenberg N, Bailer R, Isaacs A, Ledgerwood J, Seaton K, Mayer K, Corey L, Gilbert P. Pharmacokinetics Analysis of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.  Poster Presentation, CROI 2017, Seattle, WA, USA, February 13-16, 2017

Selinger C, Bershteyn A, Dimitrov DT, Hallett T, Bekker LG, Rees H, Gray G, for the Pox-Protein Public-Private Partnership Global Access Committee. Population-level Impact and Cost-effectiveness of an HIV Vaccine in South Africa. Poster Presentation, CROI 2017, Seattle, WA, USA, February 13-16, 2017